Pavel Klener

2.8k total citations
121 papers, 1.6k citations indexed

About

Pavel Klener is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Pavel Klener has authored 121 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pathology and Forensic Medicine, 49 papers in Oncology and 41 papers in Molecular Biology. Recurrent topics in Pavel Klener's work include Lymphoma Diagnosis and Treatment (54 papers), Chronic Lymphocytic Leukemia Research (37 papers) and Viral-associated cancers and disorders (18 papers). Pavel Klener is often cited by papers focused on Lymphoma Diagnosis and Treatment (54 papers), Chronic Lymphocytic Leukemia Research (37 papers) and Viral-associated cancers and disorders (18 papers). Pavel Klener collaborates with scholars based in Czechia, United States and Germany. Pavel Klener's co-authors include Magdalena Klánová, Marek Trněný, Ladislav Anděra, Petra Vočková, Pavel Otáhal, Robert Pytlík, J Živný, Dana Průková, Tomáš Etrych and Jan Molinský and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Pavel Klener

114 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pavel Klener Czechia 25 638 631 508 338 266 121 1.6k
Maki Yoshida Japan 21 571 0.9× 531 0.8× 418 0.8× 205 0.6× 157 0.6× 55 1.6k
Sherine F. Elsawa United States 20 676 1.1× 1.0k 1.6× 296 0.6× 223 0.7× 980 3.7× 57 2.3k
Blake T. Aftab United States 18 676 1.1× 839 1.3× 320 0.6× 80 0.2× 369 1.4× 38 1.6k
Francesca Margheri Italy 28 492 0.8× 1.0k 1.6× 196 0.4× 163 0.5× 303 1.1× 51 1.8k
Giorgia Simonetti Italy 25 520 0.8× 1.0k 1.6× 224 0.4× 382 1.1× 778 2.9× 91 2.2k
Jessica Dal Col Italy 20 554 0.9× 469 0.7× 202 0.4× 106 0.3× 550 2.1× 35 1.2k
Anna Sebestyén Hungary 22 464 0.7× 1.1k 1.7× 162 0.3× 153 0.5× 269 1.0× 103 1.9k
Shaojun Zhu China 20 326 0.5× 943 1.5× 140 0.3× 206 0.6× 196 0.7× 47 1.6k
Michael Amatangelo United States 15 587 0.9× 1.3k 2.0× 222 0.4× 133 0.4× 132 0.5× 50 1.9k
Sophia Adamia United States 21 251 0.4× 692 1.1× 194 0.4× 281 0.8× 169 0.6× 69 1.5k

Countries citing papers authored by Pavel Klener

Since Specialization
Citations

This map shows the geographic impact of Pavel Klener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pavel Klener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pavel Klener more than expected).

Fields of papers citing papers by Pavel Klener

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pavel Klener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pavel Klener. The network helps show where Pavel Klener may publish in the future.

Co-authorship network of co-authors of Pavel Klener

This figure shows the co-authorship network connecting the top 25 collaborators of Pavel Klener. A scholar is included among the top collaborators of Pavel Klener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pavel Klener. Pavel Klener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pola, Robert, Michal Pechar, Libor Kostka, et al.. (2025). Nanomedicines for Delivery of Cytarabine: Effect of Carrier Structure and Spacer on the Anti-Lymphoma Efficacy. Polymers. 17(21). 2837–2837.
2.
Burda, Pavel, et al.. (2024). Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events. Molecular Metabolism. 88. 102016–102016. 1 indexed citations
3.
Boudesco, Christophe, François Hermetet, Catherine Chassagne‐Clément, et al.. (2024). First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma. Leukemia. 38(8). 1742–1750. 5 indexed citations
4.
Golovina, Elena A., Juraj Kokavec, Filipp Savvulidi, et al.. (2024). Deficiency of miR-155 in Leukemic B-Cells Results in Cell Cycle Arrest and Deregulation of MIR155HG/TP53INP1/CDKN1A/CCND1 network. Archives of Medical Research. 56(3). 103124–103124. 3 indexed citations
5.
Řezníčková, Eva, Radek Jorda, Milan Dejmek, et al.. (2023). Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping. Journal of Medicinal Chemistry. 66(16). 11133–11157. 8 indexed citations
6.
Schmitt, Anja, Melanie Grimm, Caroline Schönfeld, et al.. (2023). BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 142(13). 1143–1155. 38 indexed citations
7.
Xu, Wendan, Philipp Berning, Tabea Erdmann, et al.. (2022). mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. Leukemia. 37(1). 178–189. 18 indexed citations
8.
Klener, Pavel, et al.. (2020). The benefits of ascorbate to protect healthy cells in the prevention and treatment of oncological diseases. Journal of Applied Biomedicine. 18(1). 1–7. 2 indexed citations
9.
Vočková, Petra, et al.. (2020). Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma. Folia Biologica. 66(1). 17–23. 8 indexed citations
10.
Bucher, Philip, Tabea Erdmann, Wendan Xu, et al.. (2019). Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 135(2). 121–132. 27 indexed citations
11.
Průková, Dana, Ladislav Anděra, Zuzana Nahácka, et al.. (2019). Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. Clinical Cancer Research. 25(14). 4455–4465. 63 indexed citations
12.
Jorda, Radek, Libor Havlı́ček, Md. Mahmudul Alam, et al.. (2019). 3,5,7-Substituted Pyrazolo[4,3-d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models. Journal of Medicinal Chemistry. 62(9). 4606–4623. 21 indexed citations
13.
Etrych, Tomáš, Eva Pokorná, Jan Pankrác, et al.. (2018). Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging. Journal of Controlled Release. 289. 44–55. 31 indexed citations
14.
Klánová, Magdalena, Ladislav Anděra, Jan Bražina, et al.. (2015). Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clinical Cancer Research. 22(5). 1138–1149. 72 indexed citations
15.
Molinský, Jan, Magdalena Klánová, Tomáš Soukup, et al.. (2013). In Vivo Growth of Mantle Cell Lymphoma Xenografts in Immunodeficient Mice Is Positively Regulated by VEGF and Associated with Significant Up-regulation of CD31/PECAM1. Folia Biologica. 59(1). 26–31. 4 indexed citations
16.
Cheah, Chan Y., Anupkumar George, Eva Giné, et al.. (2013). Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Annals of Oncology. 24(8). 2119–2123. 83 indexed citations
17.
Molinský, Jan, Magdalena Klánová, Ladislav Anděra, et al.. (2012). Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL). Neoplasma. 60(2). 223–231. 8 indexed citations
18.
Klener, Pavel & Pavel Klener. (2010). [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].. PubMed. 23(4). 203–9. 3 indexed citations
19.
Klener, Pavel, Ladislav Anděra, Pavel Klener, E Nečas, & J Živný. (2006). Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Apoptotic Pathways. Folia Biologica. 52(1-2). 34–44. 18 indexed citations
20.
Klener, Pavel, Ladislav Anděra, Pavel Klener, E Nečas, & J Živný. (2006). Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Therapeutic Approaches. Folia Biologica. 52(4). 119–136. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maki Yoshida Breakdown of academic impact, for papers by Sherine F. Elsawa Breakdown of academic impact, for papers by Blake T. Aftab Breakdown of academic impact, for papers by Francesca Margheri Breakdown of academic impact, for papers by Giorgia Simonetti Breakdown of academic impact, for papers by Jessica Dal Col Breakdown of academic impact, for papers by Anna Sebestyén Breakdown of academic impact, for papers by Shaojun Zhu Breakdown of academic impact, for papers by Michael Amatangelo Breakdown of academic impact, for papers by Sophia Adamia
Rankless by CCL
2026